One Microchip, $100B Estimated Market Opportunities

Breakthrough nerve-sensing technology has the potential to help treat a wide range of disorders.

For many, pain can be a constant in life, which is why painkillers are such a huge market – despite typically being a temporary (and sometimes dangerous) "band-aid" solution. Autonomix has a better idea: Target pain at its source in the nervous system. Alongside pain management, their breakthrough nerve-sensing technology has the potential to help treat a wide range of disorders including high blood pressure and digestive issues. It's all with one tiny microchip that's intended to target nerve signals at an accuracy never seen before. The team has 100+ patents issued and pending, and with an estimated total of $100B+ in markets to address, we believe it's a unique opportunity for investors. See how you can invest in Autonomix before their planned NASDAQ listing.   Learn more...   Regards, Autonomix Disclosure: This is a paid advertisement for Autonomix's Regulation A+ Offering. Please read the offering circular at invest.autonomix.com. This is a PAID ADVERTISEMENT provided to customers of Schaeffer's Investment Research. Although we have sent you this email, Schaeffer's does not specifically endorse this product nor is it responsible for the content of this advertisement. Furthermore, we make no guarantee or warranty about what is advertised above. To stop receiving these emails, unsubscribe. Schaeffer's Investment Research 5151 Pfeiffer Road, Suite 450 Cincinnati, Ohio 45242